ATIM-49 (LTBK-01). AMG 596, A NOVEL ANTI-EGFRVIII BISPECIFIC T CELL ENGAGER (BITE(®)) MOLECULE FOR THE TREATMENT OF GLIOBLASTOMA (GBM): PLANNED INTERIM ANALYSIS IN RECURRENT GBM (RGBM)

OBJECTIVES: The class III variant of the epidermal growth factor receptor (EGFRvIII) represents the most common EGFR mutation in GBM. AMG 596 is a bispecific T cell engager (BiTE(®)) molecule designed to engage a patient’s own CD3-positive T cells to EGFRvIII-positive tumor antigens. This is the fir...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Neuro Oncol
Päätekijät: Rosenthal, Mark A, Balana, Carmen, van Linde, Myra E, Sayehli, Cyrus, Fiedler, Walter M, Wermke, Martin, Massard, Christophe, Mellinghoff, Ingo K, Khasraw, Mustafa, Ang, Agnes, Rasmussen, Erik, Kast, Johannes, Stienen, Sabine, Cloughesy, Timothy F
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Oxford University Press 2019
Aiheet:
Late Breaking Abstracts
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6873614/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz219.1195
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia